By discovering the requirement of hepaCAM for localizing connexin 43, a well-established tumor suppressor, to cellular junctions and stabilizing it there, this study identifies a mechanism by which deletion of hepaCAM may support tumor progression. Here, GJA1 is linked to neoplasm.